LEIDEN, Netherlands & CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced that it intends to offer
… bring a tremendous amount of experience in the fields of RNA-based therapeutics and genetic pediatric diseases. The … of the Company’s novel and proprietary next generation RNAediting technology, Axiomer®, that utilizes endogenous …
… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNAediting technology platform, today announced the Annual …
… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today reported its … candidates, and to advance our Axiomer ® and Trident ™ RNA-editing technology platforms.” Business Operations and … ® EONs are designed to recruit an endogenously expressed RNAediting system called ADAR, which can direct the change …
… on Pipeline and Introduces Axiomer®, a novel proprietary RNA Technology Key program features and updates: ProQR to … Axiomer®: ProQR will introduce its novel, proprietary RNAediting platform technology. Art Levin, Ph.D., an …
… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today hosted a … review of the Company’s clinical-stage programs and RNAediting technology platforms. A webcast replay of the …